Russian Heart Failure Journal 2011year Feasible mechanisms of the positive action of simvastatin for integrated treatment of CHF patients with ischemic etiology

To access this material please log in or register

Register Authorize

Feasible mechanisms of the positive action of simvastatin for integrated treatment of CHF patients with ischemic etiology

Kechedgieva N. P.1, Tripoten M. I.1, Sychev A. V.1, Filatov D. N.1, Narusov O. Yu.1, Skvotzov А. А.1, Gerasimova V. V.1, Balachonova T. V.1, Masenko V. P.1, Mareev V. Yu.2
1 - Federal State Budgetary Institution, “Russian Cardiology Research and Production Complex” of the RF Ministry of Health Care, 3rd Cherepkovskaya 15a, Moscow 121552
2 - Federal State Budgetary Educational Institution of Higher Professional Education “M. V. Lomonosov Moscow State University”, Leninskie Gory 1, GSP-1, Moscow 119992

Keywords: mechanism of action, simvastatine, CHF

DOI: 10.18087/rhfj.2011.5.1560

Relevancy. There are a certain success regarding CHF patients’ therapy but death rate is still high. All major studies, subjected to retrospective analysis, when CHF patients got statins, demonstrated positive results as concerns reduction of death and hospitalization rate. However as per CORONA study the rosuvastatin therapy decreased the number of cardiovascular hospitalization due to CHF recrudescence but failed to influence on prognostication of such patients. That is why the matter of statins practicability and their influence mechanisms for CHF patients with ischemic disease is still of current interest. Objective. Evaluation of the safety and efficiency of simvastatin therapy for CHF II–III FC patients with ischemic disease as against optimum therapy. Materials and methods. The study included 30 CHF II–III FC patients complicated by ischemic disease. Patients were divided into two groups: patients of the 1-st group got 20 mg of simvastatin in addition to standard therapy; patients of the 2-st group continued the standard CHF therapy. Observation period was 6 months. Efficiency and safety of therapy were evaluated by clinical aspects dynamics of CHF, FC CHF, tolerance to physical activity, quality life of patients, number of laboratory and biochemical indices. Results. Implementation of simvastatin in accordance with standard CHF therapy for ischemic disease patients was accompanied by the improvement of clinical state, functional status and aerobic provision of physical activity. Long-term simvastatin therapy led to decrease of the left ventricle cavity space and that was accompanied by authentic improvement of myocardial contractility and ejection fraction of left ventricle as well as by improvement of endothelial function, decrease of vasoconstrictive components concentration. Simvastatin therapy didn’t lead to the development of a serious adverse reaction.
  1. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Даниелян М. О. Первые результаты национального эпидемиологического исследования – эпидемиологическое обследование больных ХСН в реальной клинической практике (по обращаемости) – ЭПОХА–О–ХСН. ЖСН. 2003;4 (3):116–121.
  2. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю., Беленков Ю. Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН). ЖСН. 2004;5 (1):4–7.
  3. Cleland JG, Swedberg K, Cohen-Solal A et al. The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the qua­lity of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Fail. 2000;2 (2):123–132.
  4. Hanna IR, Heeke B, Bush H et al. Lipid-lowering drug use is associated with reduced preva lence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006;3 (8):881–886.
  5. Fonarow GC, Heywood JT, Heidenreich PA et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153 (6):1021–1028.
  6. Franciosa JA, Wilen M, Ziesch ES, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51 (5):831–836.
  7. Даниелян М. О. Прогноз и лечение хронической сердечной недостаточности (данные 20‑и летнего наблюдения): Автореф. дис…. канд. мед. наук. – М., 2001.
  8. Петрухина А. А. Прогноз и лечение хронической сердечной недостаточности (данные 30‑и летнего наблюдения). Автореф. дис…. канд. мед. наук. – М., 2008.
  9. Беленков Ю. Н., Мареев В. Ю. Лечение сердечной недостаточности в XXI веке: достижения, вопросы и уроки доказательной медицины. Кардиология 2008;48 (2):6–16.
  10. Eriksson SV, Eneroth P, Kjekshus J et al. Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavisn Enalapril Survival Study (CONSENSUS). Clin Cardiol 1994; 17 (11):603–606.
  11. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82 (5):1724–1729.
  12. Bristow M. β-adrenergic receptor blocade in chronic heart failure. Circulation. 2000;101 (5):558–569.
  13. Bristow M. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997 Dec 4;80 (11A):26L-40L.
  14. MERIT-HF study group. Effect of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353 (9169):2001–2007.
  15. CIBIS – II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS – II): a randomized trial. Lancet. 1999;353 (9146):9–13.
  16. Packer M, Bristow MR, Cohn JN et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334 (21):1349–1355.
  17. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med. 1991;325 (5):293–302.
  18. Cleland JG, McGowan J. Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression. J Cardiovasc Pharmacol. 1999;33 (Suppl 3):S17–29.
  19. Руководство по атеросклерозу и ишемической болезни сердца. Под редакцией академика Е. И. Чазова, члена-корреспондента РАМН В. В. Кухарчука, профессора С. А. Бойцова. – М.: Медиа Медика, 2007. – 736c.
  20. Di Carli MF, Davidson M, Little R et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73 (8):527–533.
  21. Afridi I, Kleiman NS, Raizner AE, Zoghbi WA. Dobutamine echocardio­graphy in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation. 1995;91 (3):663–670.
  22. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Е. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. – М.: «Гэотар-Медиа», 2006. – 432 с.
  23. Саидова М. А. Возможности медикаментозного и хирургического восстановления сократимости жизнеспособного миокарда у больных ИБС и ДКМП с хронической недостаточностью кровообращения: Автореф. дис…. д-ра мед. наук. – М., 1999. – 39 с.
  24. Саидова М. А. Современные методы диагностики жизнеспособного миокарда. Кардиология. 2005;45 (9):47–54.
  25. Jones RH, White H, Velazquez EJ et al. STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. J Am Coll Cardiol. 2010;56 (6):490–498.
  26. Pedersen TR, Kjekshus J, Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344 (8934):1383–1389.
  27. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335 (14):1001–1009.
  28. The long-Term Investigators with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of cholesterol levels. N Engl J Med. 1998;339 (19):1349–1357.
  29. Shepherd S, Cobbe SM, Ford I et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterinamia. N Engl J Med. 1995;333 (20):1301–1307.
  30. Heart Protection Study Collaborative Group. MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360 (9326):7–22.
  31. Kjekshus J, Pedersen TR, Olsson AG et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3 (4):249–254.
  32. Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005;165 (1):62–67.
  33. Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg / dl treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90 (2):147–149.
  34. Nul D, Fernandez A, Zambrano C et al. Statins and mortality in congestive heart failure: benefit beyond cholesterol reduction? J Am Coll Cardiol. 2005;45 (suppl A):851–854.
  35. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin i in older patients with systolic heart failure. N Engl J Med. 2007;357 (22):2248–2261.
  36. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). ЖСН 2010;11 (1):3–62.
  37. The WOSCOPS study group. West of Scotland Coronary prevention study: implications for clinical practice. Eur Heart J. 1996;17 (2):163–164.
  38. Downs JR, Clearfield M, Tyroler HA et al. Air Force / Texas Coronary Atherosclerosis Prevention Study (AFCAPS / TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87 (9):1074–1049.
  39. Ridker PM. on behalf of the JUPITER Study Group. Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein Rationale and Design of the JUPITER Trial. Circulation. 2003;108 (19):2292–2297.
  40. Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005;7 (6):1059–1069.
  41. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8 (4):216–224.
  42. Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42 (11):1933–1940.
  43. Anker SD, Clark AL, Winkler R et al. Statin use and survival in patients with chronic heart failure – results from two observational studies with 5200 patients. Int J Cardiol. 2006;112 (2):234–242.
  44. Шахиджанова С. В. Оценка структурно-функционального состояния печени у больных с хронической недостаточностью кровообращения. Дис. Канд. мед. наук. – М.: 1992. – 163с.
  45. Leeper NJ, Ardehali R, deGoma EM, Heidenreich PA. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation. 2007;116 (6):613–618.
  46. Heart Protection Study Collaborative Group N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC / BHF heart protection study. J Am Coll Cardiol. 2007;49 (3):311–319.
  47. Sharma R, von Haehling S, Rauchhaus M et al. Whole blood endotoxin responsiveness in patients with chronic heart failure: the importance of serum lipoproteins. Eur J Heart Fail. 2005;7 (4):479–484.
  48. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004;43 (4):642–648.
  49. Masoudi FA. Statins for ischemic systolic heart failure. N Engl J Med. 2007;357 (22):2301–2304.
  50. Lorgelly PK, Briggs AH, Wedel H et al. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. Eur J Heart Fail. 2010;12 (1):66–74.
  51. Khush KK, Waters DD, Bittner V et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007;115 (5):576–583.
  52. Sola S, Mir MQ, Lerakis S et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47 (2):332–337.
  53. Node K, Fujita M, Kitakaze M et al. Short – term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108 (7):839–843.
  54. Rong JX, Rangaswamy S, Shen L et al. Arterial injury by cholesterol oxidation products causes endothelial dysfunction and arterial wall cholesterol accumulation. Arterioscler Thromb Vasc Biol. 1998;18 (12):1885–1894.
  55. Landmesser U, Engberding N, Bahlmann FH et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 2004;110 (14):1933–1939.
  56. Golomb BA, Dimsdale JE, White HL et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008;168 (7):721–727.
  57. Аторвастатин в лечении пациентов с ишемической болезнью сердца и дислипидемией и высоким общим риском: оценка эффективности и безопасности. Дизайн и основные результаты исследования АТЛАНТИКА. Кардиология. 2008;48 (11):4–13.
  58. Jondeau G, Dib JC, Dubourg O, Bourdarias JP. Relation of functional improvement in congestive heart failure after quinapril therapy to periphe­ral limitation. Am J Cardiol. 1997;79 (5):635–638.
  59. Скворцов A. A., Насонова С. Н., Сычев AВ и др. Эффекты длительной терапии ингибитором ангиотензинпревращающекго фермента квинаприлом, антагонистом рецепторов к ангиотензину II и комбинацией квинаприла и валсартана у больных с умеренной хронической сердечной недостаточности. Основные результаты исследования САДКО–ХСН. Кардиология. 2006;46 (1):33–51.
Kechedgieva N. P., Tripoten M. I., Sychev A. V. et al. Feasible mechanisms of the positive action of simvastatin for integrated treatment of CHF patients with ischemic etiology. Russian Heart Failure Journal. 2011;12(5):286-293.

To access this material please log in or register

Register Authorize
Ru En